KALGen Innolab

What KALGen Innolab does

KALGen Innolab, operating as PT Innolab Sains Internasional, is an Indonesian specialty medical laboratory positioned as the first Indonesia-Japan partnership laboratory focused on cancer examination and genomic testing. The company's core offering spans oncology genomics (SPOTMAS methylation-based cancer screening, Kalscreen, Comprehensive Genomic Profiling), non-invasive prenatal testing (NIPT triSure, CNV sequencing), personalized wellness genomics (GENME saliva test with 99.75% reported accuracy), cervical cancer screening (HPV testing), diabetes genetic testing (DiaGenme), and clinical pathology and microbiology services. Underlying technology combines genetic and molecular analysis including methylation detection, copy number variant sequencing, and polygenic risk scoring, with operations processed at accredited laboratories and results delivered within 30 days. The company is affiliated with Kalbe Group, one of Indonesia's largest pharmaceutical conglomerates, providing distribution and brand reach.

The business operates on a fee-for-service diagnostic model distributed through three channels: walk-in laboratory services at the Jakarta headquarters and Surabaya anatomical pathology lab, home service sample collection, and direct-to-consumer GENME saliva test kits. Customers include oncology and cancer-risk patients, expecting mothers, health-conscious individuals seeking wellness genomics, and healthcare providers requiring clinical pathology or clinical trial support. The company targets both B2C (individuals via walk-in and home service) and B2B (hospitals, clinics, medical check-up patients) segments, with advisory board members affiliated with major Indonesian institutions including Siloam Hospitals, RSCM, Tzu Chi Hospital, and EMC Healthcare. KALGen Academia serves as an educational platform hosting webinars and training for medical professionals, while KPOIN provides a consumer loyalty program. Pricing is not publicly disclosed and requires direct contact with the laboratory.

Name

KALGen Innolab

Legal name

PT Innolab Sains Internasional

Website

https://kalgeninnolab.co.id

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

51–100 employees

Short description

KALGen Innolab is an Indonesian specialty medical laboratory and the first Indonesia-Japan partnership lab, offering genomic and molecular diagnostics for cancer screening, NIPT, wellness genomics, and clinical pathology to consumers, expecting mothers, and healthcare providers across Jakarta, Surabaya, and Bandung.

Ownership category

akta.pro rank

Product category

Genomic Diagnostic Laboratory Services

NAICS

Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Genetic & Prenatal Testing Laboratories (HLAFAMAH)

akta.pro secondary industries

Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD), Clinical Research & Trial Central Laboratories (HLAFAMAL)

Keywords

• Genomic diagnostic testing
• Cancer screening laboratory
• Prenatal genetic testing
• Clinical pathology services
• Wellness genomics kits

Headquarters

HQ city

Pulogadung

HQ country

Indonesia

HQ region

Asia

Offices3 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Laboratory Diagnostic Testing Services: Medical laboratory services providing oncology genomics, personalized wellness genomics, anatomical pathology, and cervical cancer screening tests on a fee-for-service basis.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

KALGen Innolab is an Indonesia-based specialized medical laboratory (legal entity PT Innolab Sains Internasional) that provides genomic and molecular diagnostic testing services, including cancer screening (SPOTMAS, Kalscreen), non-invasive prenatal testing (NIPT triSure), wellness genomics (GENME), diabetes genetic testing (DiaGenme), prenatal test panels, and clinical and anatomical pathology services. It is positioned as the first Indonesia-Japan partnership laboratory, serving both individual consumers directly (via walk-in, home service, and saliva test kits) and healthcare providers with results delivered within approximately 30 days.

Product overview

KALGen Innolab is a specialized medical laboratory combining Indonesian and Japanese partnership, offering a comprehensive portfolio of genomic and diagnostic testing services. The core offerings include: (1) Oncology services through SPOTMAS and Kalscreen using genetic and molecular analysis for cancer detection; (2) GENME wellness genomics platform for personalized health assessments covering disease risk, nutrition, and fitness; (3) Prenatal testing including NIPT triSure and Prenatal Testpanel for maternal and fetal health; (4) DiaGenme for diabetes management through genetic testing; (5) Clinical pathology and microbiology services; and (6) KALGen Academia educational platform. The company positions itself as Indonesia's first Indonesia-Japan partnership laboratory with cutting-edge diagnostic technology delivering accurate, fast, and reliable results.

Differentiator

Problem solved

Functional benefit

Brands

• KALGen Academia: Educational and scientific information platform of KALGen Innolab, providing webinars, training, research publications, and events for medical professionals in genomics and pathology.
• GENME
• KPOIN
• triSure
• SPOTMAS
• Kalscreen

Products and services

• SPOTMAS

Quantifiable outcome

• 99.75% accuracy in genetic examination
• +1 more outcomes

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature10 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• PT Innolab Sains InternasionalcoreOthersParent company operating KALGen Innolab. PT Innolab Sains Internasional is the operating entity behind the first Indonesia-Japan partnership laboratory specializing in cancer examination and genomic testing services.
• Japanese Healthcare PartnerscoreStrategic or Co-development PartnerJapan-Indonesia partnership collaboration bringing Japanese diagnostic technology and expertise to Indonesian healthcare market. KALGen Innolab is described as the first partnership laboratory between Indonesia and Japan.
• Grup Kalbe (Kalbe Group)minorOthersKALGen Innolab operates under the Kalbe Group umbrella, sharing data and services with Grup Kalbe affiliates and partners for marketing, communication, and service provision purposes as stated in their privacy policy.
• Kemenkes (Ministry of Health Indonesia)minorOthersAdvisory board member affiliations with Indonesian Ministry of Health, demonstrating regulatory and governmental healthcare collaboration.
• Siloam HospitalsminorOthersAdvisory board members affiliated with Siloam Hospitals, indicating collaboration with major Indonesian hospital network for clinical and research purposes.
• RSCM (Rumah Sakit Cipto Mangunkusumo)minorOthersAdvisory board member affiliation with RSCM, Indonesia's national referral hospital, indicating academic and clinical research collaboration.
• Tzu Chi Hospital IndonesiaminorOthersAdvisory board member affiliation with Tzu Chi Hospital Indonesia, indicating charitable healthcare network collaboration.
• EMC HealthcareminorOthersAdvisory board member affiliation with EMC Healthcare, indicating collaboration with hospital network for clinical practices.
• RS ElisabethminorOthersAdvisory board member affiliation with RS Elisabeth, indicating collaboration with hospital for pathological and clinical services.
• Moestopo UniversityminorOthersAdvisory board member affiliation with Moestopo University (Universitas Prof. Dr. Moestopo), indicating academic research collaboration.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Novogene: Genomics services company providing next-generation sequencing, clinical diagnostics, and bioinformatics services to researchers and clinicians globally. Comparable as a genomics services provider that could enter or compete in the Indonesian clinical sequencing market.
• 23andMe: DTC consumer genomics company offering health, ancestry, and wellness genetic testing through saliva kits. Comparable as a DTC saliva-kit wellness genomics player overlapping with KALGen's GENME wellness genomic service.

Broad incumbents

• BGI Genomics: China-based global genomics company offering NIPT, cancer screening, and clinical sequencing services across multiple geographies. Comparable as a large-scale genomics services provider with NIPT and cancer screening offerings overlapping KALGen's portfolio.
• Illumina: Global leader in DNA sequencing technology and genomics platforms used by clinical labs, hospitals, and research institutions. Comparable as an upstream incumbent enabling genomics laboratories worldwide, including specialty labs like KALGen Innolab.

Direct peers

• Prodia Widyahusada: Indonesia's largest clinical laboratory chain offering clinical pathology, molecular diagnostics, and specialized testing nationwide. Directly comparable as a multi-site Indonesian lab competing for the same physician and consumer testing volumes that KALGen Innolab targets.
• Prenetics: Hong Kong-headquartered genomics and DTC testing company operating across Asia-Pacific with cancer screening and consumer genetic tests. Comparable as an Asia-Pacific DTC + B2B genomics player competing for regional cancer screening and wellness genomics demand.
• Parahita Diagnostic Center: Indonesian clinical laboratory network providing clinical pathology, microbiology, and specialized testing services to healthcare providers and consumers. Comparable as a domestic multi-channel Indonesian lab with overlapping clinical pathology and B2B/B2C service model.
• Myriad Genetics: US-based specialty molecular diagnostics company offering hereditary cancer testing, oncology genomic profiling, and prenatal screening. Comparable as a genomic testing platform with cancer screening and comprehensive genomic profiling menu overlapping SPOTMAS, Kalscreen, and CGP.
• Kimia Farma Diagnostika: Subsidiary of Kimia Farma (state-linked pharma) operating clinical laboratories across Indonesia. Comparable as a corporate-backed Indonesian clinical lab chain serving walk-in consumers, hospitals, and corporate medical check-up clients.
• Natera: US-based specialty diagnostics company focused on NIPT, oncology genomic profiling, and organ transplant monitoring. Comparable as a specialty genomics lab with a strong NIPT offering (parallel to NIPT triSure) and oncology genomic profiling (parallel to KALGen's CGP).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/KalgenInnolab.ID
• LinkedInlinkedin.com/company/kalgen-innolab

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about KALGen Innolab